SUZ12 and neurofibroma: To determine if PRC2 inactivation was sufficient for selumetinib resistance, we used CRISPR interference (CRISPRi) to suppress SUZ12 or EED in NF1-mutant NF95.11b neurofibroma cells (Fig. 2b).